CRISPR Therapeutics
OrganizationHeard in 5 episodes across 4 shows since Apr 2026
CRISPR Therapeutics is a biotechnology company developing gene-editing therapies based on CRISPR/Cas9 technology, including treatments for blood disorders, cancers, and other serious diseases.
Episodes
First heard
Expert statements
Episodes per month
Public PodLume episodes featuring it, over the last year.
Show the data
| Month | Episodes |
|---|---|
| Dec 2025 | 0 |
| Jan 2026 | 0 |
| Feb 2026 | 0 |
| Mar 2026 | 0 |
| Apr 2026 | 1 |
| May 2026 | 0 |
| Jun 2026 | 0 |
| Jul 2026 | 0 |
| Aug 2026 | 0 |
| Sep 2026 | 1 |
| Oct 2026 | 2 |
| Nov 2026 | 1 |
Email alert
Email me when CRISPR Therapeutics comes up on a podcast
One email a week at most, with the new episodes that mention CRISPR Therapeutics. Free, no account needed, unsubscribe in one click.
What experts have said about CRISPR Therapeutics
1 statement · 1 mixed
CRISPR Therapeutics is interesting long term but unattractive for 2026.
“Long term, very interesting. Short term, 2026, not interested.”
Open the episode · RBA raises rates again, Pimp my Portfolio with Henry Jennings & we review the community portfolioListen at 31:35
Statements are attributed to the speaker as said on the episode and reflect their view at the time, not PodLume's. They are not advice.
Episodes
5 episodes featuring CRISPR Therapeutics, newest first
- Nov 15, 2026
Biotech investors weigh gene editing, MASH data and RAS riskBreaking BiotechNov 15, 2026 - Oct 29, 2026
Fund labels obscure the AI bets hiding in portfoliosExcess Returns Oct 29, 2026 - Oct 10, 2026
Biotech ETFs frame a week of company-specific movesBreaking BiotechOct 10, 2026 - Sep 21, 2026
Cathie Wood bets convergence will reshape healthcare and AIEquity Mates Investing PodcastSep 21, 2026 - Apr 28, 2026
Cramer weighs a market reset against Iran-driven riskMad Money w/ Jim CramerApr 28, 2026